EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Neutralization of SARS‐CoV‐2 Omicron XBB.1.5 and JN.1 variants after COVID‐19 booster‐vaccination and infection

David N Springer, Jeremy V Camp iD, Stephan W Aberle, Josef Deutsch, Oliver Lammel, Lukas Weseslindtner iD, Karin Stiasny iD, Judith H Aberle iD

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29801 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von David N Springer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Virology, Medical University of Vienna, Wien, Austria. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, COVID-19, Antibodies, Viral, SARS-CoV-2. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medizinisch-wissenschaftlicher Fonds des Bürgermeisters der Stadt Wien.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SARS‐CoV‐2 Omicron lineages continue to emerge and evolve into new sublineages, causing infection waves throughout 2022 and 2023, which has been attributed to immune escape. We examined neutralizing antibody responses to the recently emerged SARS‐CoV‐2 JN.1 variant in comparison to ancestral D614G and Omicron BA.1, BA.2, BA.5, and XBB.1.5 variants. We tested 79 human sera from cohorts with different combinations of vaccinations and infections, including 23 individuals who had been repeatedly exposed to Omicron. Individuals with a monovalent XBB.1.5 vaccine booster or XBB.1.5 breakthrough infection had robust antibody levels against all variants tested; however, JN.1 evaded antibodies in individuals after single Omicron BA.1, BA.2 or BA.5 breakthrough infections. Moreover, in the non‐vaccinated cohort, serum antibodies demonstrated almost no cross‐neutralization activities against D614G, XBB.1.5 and JN.1. after infections with earlier Omicron variants. These findings show that SARS‐CoV‐2‐immunity is heterogeneous, depending on different combinations of vaccinations and infections, and emphasize the importance of considering different immune‐backgrounds when evaluating novel variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingCOVID-19Antibodies, ViralSARS-CoV-2COVID-19 VaccinesImmunization, SecondaryHumansFemaleMaleAdultMiddle AgedVaccinationNeutralization TestsAged

Stichwörter der Autor:innen

JN.1Omicron 2.86Omicron breakthrough infectionXBBneutralizing antibodies

Substanzen

Antibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccines

Autor:innen und Institutionen

  • Center for Virology, Medical University of Vienna, Wien, Austria.
  • Independent Researcher, Völkermarkt, Austria.
  • Independent Researcher, Ramsau am Dachstein, Austria.

ORCID-Profile: Jeremy V Camp, Lukas Weseslindtner, Karin Stiasny, Judith H Aberle

Förderung

  • Medizinisch-wissenschaftlicher Fonds des Bürgermeisters der Stadt Wien

Zitieren

APA

Springer, D. N., Camp, J. V., Aberle, S. W., Deutsch, J., Lammel, O., Weseslindtner, L., Stiasny, K., & Aberle, J. H. (2024). Neutralization of SARS‐CoV‐2 Omicron XBB.1.5 and JN.1 variants after COVID‐19 booster‐vaccination and infection. Journal of Medical Virology. https://doi.org/10.1002/jmv.29801

Vancouver

Springer DN, Camp JV, Aberle SW, Deutsch J, Lammel O, Weseslindtner L, et al. Neutralization of SARS‐CoV‐2 Omicron XBB.1.5 and JN.1 variants after COVID‐19 booster‐vaccination and infection. Journal of Medical Virology. 2024. doi:10.1002/jmv.29801

BibTeX
@article{Springer2024,
  author = {Springer, David N and Camp, Jeremy V and Aberle, Stephan W and Deutsch, Josef and Lammel, Oliver and Weseslindtner, Lukas and Stiasny, Karin and Aberle, Judith H},
  title = {Neutralization of SARS‐CoV‐2 Omicron XBB.1.5 and JN.1 variants after COVID‐19 booster‐vaccination and infection},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29801}
}
Kostenlos starten →